Country
Full text data for US and EP
Status
Type
Filing Date
Publication Date
Inventor
Assignee
Click to expand
IPC
No.
Publication Number
Title
Publication/Patent Number Publication/Patent Number
Publication date Publication date
Application number Application number
Filing date Filing date
Inventor Inventor
Assignee Assignee
IPC IPC
1
US20190016807A1
Publication/Patent Number: US20190016807A1
Publication date: 2019-01-17
Application number: 15/881,611
Filing date: 2018-01-26
Abstract: The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity. The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including ...more ...less
2
US20190002552A1
Publication/Patent Number: US20190002552A1
Publication date: 2019-01-03
Application number: 16/002,932
Filing date: 2018-06-07
Abstract: Formulations comprising an anti-IL-13 antibody are provided, including pharmaceutical formulations and methods of using such formulations.
3
US20190002560A1
Publication/Patent Number: US20190002560A1
Publication date: 2019-01-03
Application number: 15/735,947
Filing date: 2016-06-11
Assignee: ALECTOR LLC
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof. The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and use of ...more ...less
4
US20190002569A1
Publication/Patent Number: US20190002569A1
Publication date: 2019-01-03
Application number: 16/120,514
Filing date: 2018-09-04
Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1/OBR complex signaling pathway. In particular, the present invention relates to a method for treating a disease selected from the group consisting of cancers, obesity and obesity related diseases, anorexia, autoimmune diseases and infectious diseases in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an antagonist of the NRP-1/OBR signaling pathway. The present invention relates to methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1/OBR complex signaling pathway. In particular, the present invention relates to a method for treating a disease selected from the group consisting of ...more ...less
5
US20190002579A1
Publication/Patent Number: US20190002579A1
Publication date: 2019-01-03
Application number: 15/961,968
Filing date: 2018-04-25
Abstract: Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids. Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions ...more ...less
6
US20190002583A1
Publication/Patent Number: US20190002583A1
Publication date: 2019-01-03
Application number: 16/068,333
Filing date: 2017-01-06
Inventor: Li, Lixin  
Abstract: A combination which comprises an effective amount of Her2/Neu antagonist and an effective amount of immunotherapeutic that is capable of activating a human plasmacytoid dendritic cell, myeloid dendritic cell, NK cell, or a combination thereof is disclosed.
7
US20190015336A1
Publication/Patent Number: US20190015336A1
Publication date: 2019-01-17
Application number: 16/032,025
Filing date: 2018-07-10
Abstract: A pharmaceutical dosage form which comprises a lactide, glycolide or lactide-glycolide polymer, a block polymer of polyglycolide, trimethylene carbonate, poly-caprolactone, and polyethylene oxide that is combined with a peptide or protein therapeutic agent in the form of microparticles which are compressed using a pressure of 50,000 to 350,000 psi. A pharmaceutical dosage form which comprises a lactide, glycolide or lactide-glycolide polymer, a block polymer of polyglycolide, trimethylene carbonate, poly-caprolactone, and polyethylene oxide that is combined with a peptide or protein therapeutic agent in the form of ...more ...less
8
US20190015363A1
Publication/Patent Number: US20190015363A1
Publication date: 2019-01-17
Application number: 16/034,064
Filing date: 2018-07-12
Abstract: Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.
9
US20190015422A1
Publication/Patent Number: US20190015422A1
Publication date: 2019-01-17
Application number: 16/070,980
Filing date: 2017-01-25
Abstract: The present invention relates to methods of treating brain metastases using synergistic combinations of anti-PI3K and anti-mTOR therapies. It has also been determined that blocking PI3K and mTOR provides therapeutic benefit for treating brain metastases.
10
US20190015494A1
Publication/Patent Number: US20190015494A1
Publication date: 2019-01-17
Application number: 15/750,607
Filing date: 2016-08-05
Abstract: Provided are compositions that include one or more peptides, wherein each peptide is at least 8 amino acids long and has an amino acid sequence as set forth in any of SEQ ID NOs: 1-45. Also provided are in vitro populations of dendritic cells that include the disclosed compositions, in vitro populations of CD8+ T cells capable of being activated upon being brought into contact with the disclosed populations of dendritic cells, antibodies or antibody-like molecules that specifically bind to complexes of MHC class I molecules and the disclosed peptides, methods for treating and/or preventing cancer such as leukemia using the disclosed compositions and/or populations, methods for making cancer vaccines using the disclosed compositions, methods for screening target peptides for inclusion in an immunotherapy composition, methods for determining a prognosis of a leukemia patient, and kits that include at least one of the disclosed peptides. Provided are compositions that include one or more peptides, wherein each peptide is at least 8 amino acids long and has an amino acid sequence as set forth in any of SEQ ID NOs: 1-45. Also provided are in vitro populations of dendritic cells that include the disclosed ...more ...less
11
US20190015503A1
Publication/Patent Number: US20190015503A1
Publication date: 2019-01-17
Application number: 15/745,211
Filing date: 2016-07-13